CN104706673A - Adipose-derived mesenchymal progenitor cells for treatment of hepatitis B - Google Patents
Adipose-derived mesenchymal progenitor cells for treatment of hepatitis B Download PDFInfo
- Publication number
- CN104706673A CN104706673A CN201310689278.XA CN201310689278A CN104706673A CN 104706673 A CN104706673 A CN 104706673A CN 201310689278 A CN201310689278 A CN 201310689278A CN 104706673 A CN104706673 A CN 104706673A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- cell
- cfu
- fat mesenchymal
- surface antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a use of adipose-derived mesenchymal progenitor cells in prevention or treatment of hepatitis. In particular, the adipose-derived mesenchymal progenitor cells can be used for preparing a pharmaceutical composition for treatment of hepatitis B. A requiring object is applied with the pharmaceutical composition, the indexes of hepatitis B surface antigens, hepatitis B surface antibodies, hepatitis B e antigens, hepatitis B e antibodies, hepatitis B core antibodies and the like can be improved, the hepatitis virus DNA is significantly reduced, ALT is decreased, and thus restoration of liver functions is promoted.
Description
Technical field
The present invention relates to fat stem cell application, particularly, the invention provides the purposes that a kind of fat stem cell is used for the treatment of hepatitis B.
Background technology
Hepatopathy is divided into viral liver disease and non-viral hepatitis.Viral hepatitis mainly comprise first, second, third, fourth, hepatitis E, Non-viral liver disease mainly comprises alcoholic liver disease, medicine or poisonous substance hepatopathy, pathobolism hepatopathy, fatty liver disease.Chronic hepatitis B is distribution on global, may cause comprising liver function and lose the diseases such as compensatory, liver cirrhosis and hepatocarcinoma.It is the major driving factor of hepatic injury and progression of disease that activeness hepatitis B virus (HBV) copies.
Heavy hepatitis B infects the hepatitis gravis caused after HBV, and its morbidity is dangerous, and progress is rapid, and Most patients's prognosis mala, can occur rapidly that large area hepatic necrosis causes liver function to be badly damaged, the hypofunction of liver metabolism, excretion and deciphering.Thus cause body immunity to decline, cause vicious cycle.Lack effective treatment means clinically at present, mainly plasmapheresis and liver transplantation, but due to donor shortage, a lot of patient is dead during wait transplantation donor.Therefore, liver function support timely and effectively and promotion liver cell regeneration may help liver failure patient to recover voluntarily without the need to liver transplantation or spend the difficulty waited for and transplanting.
Conventional medicament interferon-alpha can suppress virus replication effectively, and curative effect is relatively lasting, but its crowd's narrow range be suitable for, adverse reaction rate is higher.And the interferon of a new generation-PVOH interferon, its curative effect is slightly better than plain interferon, but its still have use patient group narrow, adverse reaction rate is higher, the shortcoming that price is more expensive.Lamivudine is first nucleoside analog, can suppress virus replication fast, lastingly, improve liver function, delay the medicine of hepatitis B diseases progress, but its HBeAg serum negative conversion rate is low.It is about 16% that bibliographical information takes lamivudine 1 year HBeAg serum negative conversion rate, easily recurrence after drug withdrawal, virus thoroughly can not be removed and be extended with treatment time, and the incidence rate of viral medicament-resistant mutation increases (within the 1st, 2,3,4 year, being respectively 14%, 38%, 49%, 66%).Adefovir ester long-term treatment drug resistance incidence rate is low, still effective to lamivudine resistance person, but its antivirus action is more weak, and onset is slow, has potential nephrotoxicity.The antivirus action of Entecavir is strong, and resistant rate is low, find carcinogenecity, and price is more expensive in zoopery.Sebivo antivirus action is strong, and HBeAg conversion ratio is high, but its aberration rate is higher, and have the side effect such as creatine kinase rising, Time To Market is short, antivirus action, and long-term efficacy and safety all remain to be confirmed.Nucleoside (acid) similar medicine all can not at will drug withdrawal, and long-term taking hepatitis B virus morphs drug resistance easily, also there will be picture influenza sample, anorexia, feel sick, diarrhoea, depression, the side effect such as angina pectoris.And antiviral therapy can only inhibition HBV replication, thoroughly can not remove virus, also cannot repair the hepatic necrosis that hepatitis causes.
At present, the treatment of hepatitis B mainly antiviral therapy.And the antiviral drugs of present stage can only inhibition HBV replication, still thoroughly can not remove virus, also cannot repair the hepatic necrosis that hepatitis causes.Therefore easily form chronic viral hepatitis B after infecting hepatitis B virus, likely cause the generation such as liver cirrhosis, hepatocarcinoma.
In sum, this area still lacks one effectively can treat hepatitis B, particularly thoroughly can remove hepatitis B virus, repairs the means of the hepatic necrosis that hepatitis causes.
Summary of the invention
The object of the present invention is to provide one effectively can treat hepatitis B, particularly thoroughly can remove hepatitis B virus, repair the means of the hepatic necrosis that hepatitis causes.
A first aspect of the present invention, provides a kind of purposes of fat mesenchymal CFU-GM, it is characterized in that, for the preparation of the pharmaceutical composition for the treatment of hepatitis B.
In another preference, described fat mesenchymal CFU-GM is the fat mesenchymal CFU-GM of Secondary Culture.
In another preference, in the composition, main active is only fat mesenchymal CFU-GM.
In another preference, in described compositions, the content of described fat mesenchymal CFU-GM is 1 × 10
5/ ml-1 × 10
8/ ml.
In another preference, described pharmaceutical composition comprises: fat mesenchymal CFU-GM, and pharmaceutically acceptable carrier.
In another preference, described carrier is infusion solution carrier and/or injection carrier.
In another preference, described treatment comprises the one or more target improvement being selected from lower group:
Hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B virus e antigen, hepatitis B e antibody, hepatitis B core antibody, hepatitis B virus DNA, and ALT.
In another preference, described fat mesenchymal CFU-GM has the arbitrary or various features being selected from lower group:
I the cell of () more than 80% has surface antigen CD29;
(ii) cell of more than 70% has surface antigen CD73;
(iii) cell of more than 60% has surface antigen CD105;
(iv) cell of more than 70% has surface antigen CD90.
In another preference, the cell of more than 90% has surface antigen CD29.
In another preference, the cell of more than 80% has surface antigen CD73.
In another preference, the cell of more than 70% has surface antigen CD105.
In another preference, the cell of more than 80% has surface antigen CD90.
In another preference, described fat mesenchymal CFU-GM has the arbitrary or various features being selected from lower group:
V (), in cell mass, the cell of less than 10% has surface antigen CD34;
(vi) in cell mass, the cell of less than 10% has surface antigen CD45.
In another preference, the cell of less than 5% has surface antigen CD34.
In another preference, the cell of less than 5% has surface antigen CD45.
In another preference, the cell of less than 1% has surface antigen CD34.
In another preference, the cell of less than 1% has surface antigen CD45.
A second aspect of the present invention, provide a kind of pharmaceutical composition for preventing or treat hepatitis, described pharmaceutical composition comprises: the fat mesenchymal CFU-GM of effective dose, and pharmaceutically acceptable carrier.
In another preference, described pharmaceutically acceptable carrier comprises (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and combination thereof.
In another preference, described pharmaceutical composition is intravenous injection reagent.
In another preference, in described intravenous injection reagent, the concentration of fat mesenchymal CFU-GM is 0.1-100 × 10
4individual/ml is preferably 1-10 × 10
4individual/ml is more preferably 2-5 × 10
5individual/ml.
In another preference, the volume of described injection reagent is 30-70ml.
A third aspect of the present invention, provide a kind of method of prevention or treatment hepatitis, comprise step: use fat mesenchymal CFU-GM or fat mesenchymal progenitor cell to the object of needs or contain the pharmaceutical composition of fat mesenchymal CFU-GM or fat mesenchymal progenitor cell.
In another preference, described object is behaved or non-human mammal.
In another preference, described non-human mammal is Mus, rabbit, cattle, sheep, pig etc.
In another preference, described method of application is venous re-transfusion.
Should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the present invention and can combining mutually between specifically described each technical characteristic in below (eg embodiment), thus form new or preferred technical scheme.As space is limited, tiredly no longer one by one to state at this.
Accompanying drawing explanation
The oil red O stain of Fig. 1 Adipocyte Differentiation;
The oil red O stain matched group (feminine gender) of Fig. 2 Adipocyte Differentiation;
Fig. 3 osteoblast differentiation Alizarin red staining detects;
Fig. 4 osteoblast differentiation Alizarin red staining detects matched group (feminine gender), and undifferentiated cell dyeing is negative;
Fig. 5 flow cytometer detection test collection of illustrative plates.
Detailed description of the invention
The present inventor, through long-term and deep research, is surprised to find that, fat mesenchymal CFU-GM has the effect of extremely excellent prevention or treatment hepatitis (especially hepatitis B).Particularly, use the pharmaceutical composition containing fat mesenchymal CFU-GM of the present invention to the object needed, have significant prevention or therapeutical effect for hepatitis, kinds of surface antigen can be made to decline, viral DNA significantly reduces, and lowers ALT, promotes the reparation of liver function.On this basis, inventor completes the present invention.
Term
As used herein, term " more than " and " below " comprise this number, such as " more than 95% " refer to >=95%, and " less than 0.2% " refer to≤0.2%.
Hepatitis B
Hepatitis B, is called for short hepatitis B, is disease caused after one infects body by hepatitis B virus (HBV).
Hepatitis B virus host range is narrow, and has significantly addicted to liver property, and In vitro culture difficulty is large.Hepatitis B model relates to hepatitis B virus infection and organism immune response after infecting, and therefore not only needs over the course for the treatment of to repair liver damage cell, also needs to suppress body inner virus to copy and immunity moderation reaction, has larger difference with non-viral hepatitis.At present, animal model mainly utilizes the animal of immunodeficiency to make people HBV animal model.Its require mainly with people's clinical hepatitis feature similarity, in viremia and blood, amynologic index maintains certain hour, reduces the morbid state of hepatitis B virus infection human body to the full extent.And non-viral hepatitis model, such as Alcoholic Liver Disease Model, drug induced hepatitis model etc. are directly intervened by diet or medicine, damaged animal liver cell function, the clinical manifestation of simulation human body hepatitis.
Common hepatitis B Testing index " five indexes of hepatitis b " comprises hepatitis B surface antigen, hepatitis B surface antibody, e antigen, e antibody, core antibody.Surface antigen is the coat protein of hepatitis B virus, and self does not have infectiousness, but its appearance is often along with the existence of hepatitis B virus, and therefore its positive is infected the mark of hepatitis B virus.Usually infecting virus latter 2-6 month, when serum transaminase does not also rise, just the positive can be measured in serum.The acute hepatitis b patient overwhelming majority can turn out cloudy at the course of disease initial stage, but Chronic Hepatitis B can lasting masculin.Surface antibody is to hepatitis B virus immune and protection antibody in body, how to occur positive in convalescent period.Meanwhile, accept hepatitis B vaccinate person, the overwhelming majority is also positive.E antigen is usually after hepatitis B virus infection, and the while of surface antigen positive, or a couple of days just can record the positive thereafter.E antibody positive several months after antigen is turned out cloudy occurs.Core antibody is 3-5 week after surface antigen occurs generally, and hepatitis B symptom just can check out before occurring in serum.
In the present invention, for the treatment of hepatitis B mainly in hepatitis B virus index of correlation such as reverse five indexes of hepatitis b etc., comprise (but being not limited to): hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B virus e antigen, hepatitis B e antibody, hepatitis B core antibody, hepatitis B virus DNA, and ALT.
Fat
Autologous fat is the Excellent sources of shaping and antidotal therapy, and fatty tissue material can derive from the positions such as waist, buttocks, abdominal part, thigh, upper arm.Those skilled in the art can adopt general technical method to obtain autologous adipose tissue, include, but is not limited to the method such as suction, operation separation.
In the present invention, fatty tissue or fatty raw material are not particularly limited, and can be the fatty tissuees at any position deriving from animal or human, the fatty tissue of preferred people.Preferably, fatty tissue can be the tissue at the positions such as waist, buttocks, abdominal part, thigh, upper arm.
Fat mesenchymal CFU-GM (Human adipose derived mesenchymal progenitor cells)
Adipose-derived mesenchymal stem/progenitor cells (Human adipose derived msenchymal progenitorcells, haMPCs): not containing CD34+ cell, SVF cultivates P3-P10 and obtains for purification amplification.
In the present invention, the preparation method of fat mesenchymal CFU-GM can comprise step: washing fatty tissue, then uses collagenase digesting, centrifugalize stromal vascular fraction, except degrease and collagenase, cultivate primary cell, obtain the fat mesenchymal CFU-GM after going down to posterity.
The Detection of antigen of fat mesenchymal CFU-GM
By the fat mesenchymal CFU-GM that the present invention uses, there is very high purity, be substantially devoid of cell or the stem cell of other types.This detection by cell surface antigen is verified.
Fat mesenchymal CFU-GM has multiple specific antigen and receptor, mainly contains CD3, CD13, D29, CD34, CD45, CD49e, CD59, CD73, CD90, CD105, HLA-ABC etc.
CD34 antigen is a kind of high glycosylation I type transmembrane protein, it is optionally expressed in mankind hemopoietic stem cell (HSC), CFU-GM (PC) and vascular endothelial cell (EC) surface, fat mesenchymal CFU-GM with CD34 is preferably≤0.2% in the ratio of total stem cell, more preferably ,≤0.2%.
CD45 is present in the surface of all hematopoietic cells, comprises hematopoietic stem cell and osteoclast.Fat mesenchymal CFU-GM with CD45 is preferably≤0.1% in the ratio of total stem cell.
CD29, CD73, CD49d, CD90 etc. are mainly present in fat mesenchymal stem cell surface.
Fat mesenchymal CFU-GM with CD29 is preferably >=30%, more preferably >=32%, best >=35% in the ratio of total stem cell.
Fat mesenchymal CFU-GM with CD73 is preferably >=50%, more preferably >=60%, best >=70% in the ratio of total stem cell.
Fat mesenchymal CFU-GM with CD49d is preferably >=85%, more preferably >=90%, best >=95% in the ratio of total stem cell.
Fat mesenchymal CFU-GM with CD90 is preferably >=55%, more preferably >=60%, best >=65% in the ratio of total stem cell.
Those skilled in that art can use general method to detect purity and the differentiation degree of fat mesenchymal CFU-GM, as Flow cytometry.During detection, add different from specific antibody targetedly, antibody can be complete monoclonal or polyclonal antibody, also can be have immunocompetent antibody fragment, as Fab ' or (Fab) 2 fragment; Heavy chain of antibody; Light chain of antibody; Genetically engineered Single Chain Fv Molecule A (people such as Ladner, U.S. Patent No. 4,946,778); Or chimeric antibody, as there is murine antibody binding specificity but still retaining the antibody from the antibody moiety of people.The antigen adding antibody and cell surface, in conjunction with certain hour, carries out automatic analysis and sorting with flow cytometer to cell.
Pharmaceutical composition
Present invention also offers a kind of pharmaceutical composition, it contains the fat mesenchymal CFU-GM of effective dose, and pharmaceutically acceptable carrier.
Usually, fat mesenchymal CFU-GM can be formulated in nontoxic, inertia with in pharmaceutically acceptable aqueous carrier medium, as in normal saline, wherein pH is about 5-8 usually, and preferably, pH is about 7-8.
As used herein, term " effective dose " or " effective dose " refer to can to people and/or animal produce function or activity and can by people and/or animal the amount that accepts.
As used herein, the composition of " pharmaceutically acceptable " is applicable to people and/or mammal and without excessive bad side reaction (as toxicity, stimulation and allergy), namely has the material of rational benefit/risk ratio.Term " pharmaceutically acceptable carrier " refers to the carrier being used for the treatment of agent administration, comprises various excipient and diluent.
Pharmaceutical composition of the present invention contains the fat mesenchymal CFU-GM of safe and effective amount and pharmaceutically acceptable carrier.This kind of carrier comprises (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and combination thereof.Usual pharmaceutical preparation should match with administering mode, and pharmaceutical composition of the present invention can be made into injection form, such as, be prepared by conventional method with normal saline or the aqueous solution containing glucose and other adjuvant.Described pharmaceutical composition should aseptically manufacture.The dosage of active component is treatment effective dose.Pharmaceutical preparation of the present invention also can be made into slow releasing preparation.
The effective dose of fat mesenchymal CFU-GM of the present invention can change with order of severity of the pattern of administration and disease to be treated etc.The selection of preferred effective dose can be determined (such as passing through clinical trial) according to various factors by those of ordinary skill in the art.Described factor includes but not limited to: described pharmacokinetic parameter is bioavailability, metabolism, half-life etc. such as; The order of severity of the disease that patient will treat, the body weight of patient, the immune state of patient, the approach etc. of administration.
Pharmaceutical composition of the present invention is preferably subcutaneous or intravenous injection reagent.In another preference, in described subcutaneous or intravenous injection reagent, the concentration of fat mesenchymal CFU-GM is 1 × 10
3-2 × 10
6individual/ml is preferably 1 × 10
4-1 × 10
6individual/ml is more preferably 1 × 10
5-5 × 10
5individual/ml.
Major advantage of the present invention:
(1) fat mesenchymal CFU-GM has significant prevention or therapeutical effect for hepatitis (particularly hepatitis B), particularly shows as the reverse of the hepatitis B virus indexs of correlation such as hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B virus e antigen, hepatitis B e antibody, hepatitis B core antibody;
(2) fat mesenchymal CFU-GM makes hepatitis B cell kinds of surface antigen decline, and viral DNA significantly reduces, and lowers glutamate pyruvate transaminase ALT;
(3) fat mesenchymal CFU-GM can promote the reparation of liver function.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually conveniently condition, or according to the condition that manufacturer advises.Unless otherwise indicated, otherwise percentage ratio and number calculate by weight.
The cultivation of embodiment 1 fat mesenchymal CFU-GM
1. sterile surgical instrument and consumptive material
(1) aseptic long handle operation surgical forceps 5
(2) aseptic 100 mesh filter screens
(3) sterilizing 40 mesh filter screen
(4) 50ml centrifuge tube
(5) T175, T75 culture bottle
(6) T10ml, T25ml pipet
(7) wide-bore tip pipet
2. aseptic reagent:
(1) StemPro zero RMSC SFM culture medium (life)
(2) type i collagen enzyme (now with the current): 0.1% collagenase I compound method: take 0.1g collagenase I powder dissolution and do not add in 100ml in the culture medium of any factor, with before 37 DEG C carry out preheating.
(3) sodium chloride injection
(4) 0.125%Trypsin-0.01%EDTA solution
Embodiment
1. receive fatty tissue, with the container outer wall of the alcohol wipe dress fatty tissue of 75%;
2. subpackage fatty tissue, each T175 culture bottle subpackage fatty tissue is 50ml.10ml pipet, removes suction nozzle, first draws lower floor's red liquid and discard in fat acquisition bottle, carries out subpackage after the mixing of residue upper-layer fat.
3. wash fatty tissue, removing hemocyte.In T175 culture bottle, add 100ml sodium chloride injection, tighten lid, acutely rock 3 minutes fully to wash fatty tissue, then static 3-5 minute, difference is separated, suck lower floor's aqueous phase; Repeat above operation three times, until subnatant becomes limpid.
4. collagenase I digests: the collagenase I solution adding the preheating (half an hour is in the gas bath shaking table preheating of 37 DEG C in advance) that equivalent is newly prepared, sealed membrane seals, acutely rock culture bottle 5 ~ 10 seconds, be placed in vibration gas bath pot, 37 DEG C, 70rpm, digests 60 minutes, culture bottle is acutely rocked 5 ~ 10 seconds, until seem comparatively level and smooth every 15 minutes.
5. isolation medium vascular component (SVF): be dispensed in the centrifuge tube of 50ml by aseptic 40 mesh filter screens of postdigestive tissue, centrifugal 10 minutes of room temperature 400g, the precipitation obtained is SVF.
6. purification precipitation: after centrifugal, SVF is deposited on bottom centrifuge tube, carefully removes the collagenase solution of upper strata oils and fats and lower floor from top to bottom with pipet.Attention: leave a small amount of solution, in order to avoid disturbance sedimentation cell above SVF precipitation.Appropriate normal saline re-suspended cell, dispels, room temperature 400g, and 10 minutes centrifugal.Centrifugal complete, carefully suck supernatant, can not directly outwell.During absorption, head of pipette should be placed in the top of centrifuge tube so that thoroughly except deoiling.10ml culture medium suspension cell, is then aggregated into cell in 50ml centrifuge tube, and cross 100 mesh sieves, again room temperature 300g, 10 minutes centrifugal.
7. cell seeding: add 20ml culture medium after centrifugal and fully mix.Based on tissue block method: the area according to culture bottle carries out cell seeding.The fat mass obtained according to every square centimeter of inoculation 0.16ml liposuction is inoculated, and namely inoculates 12ml liposuction fat mass in each T75 culture bottle.I.e. every 100ml fatty tissue, finally can inoculate 8 T75 culture bottles.The cell suspension conversion carried out untreated fat mass and finally obtain, and then inoculating cell.
8. primitive cell culture:
8.1 horizontal culture bottles, are positioned over carbon dioxide constant temperature and humidity incubator by culture bottle.Condition of culture: 37 ± 0.5 DEG C, carbon dioxide volume fraction is 5 ± 0.2%.
8.2 change liquid: original cuiture the 24th hour, carry out full dose and change liquid.After this change liquid every 3 days full doses, place carbon dioxide constant temperature and humidity incubator and cultivate.
9. primary cell results: about 7 days, when the area percentage of the cell clone group of original cuiture arrives 70% ~ 80%, digestion results.
9.1 primary cell results: (digestive enzyme is 0.125%Trypsin-0.01%EDTA solution, uses front room temperature (20 ~ 25 DEG C) to place 15 ~ 25min, every 75cm to add digestive enzyme in culture bottle
2add 2ml digestive enzyme solution), digestion time is 1.5 ~ 2.5min, add at the bottom of culture medium 2 ~ 3ml blows and beats bottle repeatedly and come off to cell major part, move in 50ml centrifuge tube, in former culture bottle, add 4 ~ 5ml sodium chloride injection rinsing bottle wall, add in centrifuge tube and be settled to 50ml, after pipet piping and druming suspends, the aseptic strainer filtering of 100 order, filtrate is collected in 50ml centrifuge tube, 1000rpm, 10min centrifuge washing.
9.2 primary cells go down to posterity: observe remaining cell precipitation amount in single centrifuge tube, and suitably merge in several centrifuge tube in cell precipitation to 1 centrifuge tube, add appropriate culture medium, blow and beat resuspension cell gently, be settled to 30ml, piping and druming mixes, sampling counting.1000rpm, 10min secondary centrifuging after counting.Remove supernatant, in centrifuge tube, add culture medium in right amount, blow and beat resuspension cell gently, be seeded in new culture vessel after standardize solution, passage cell density is 5000 ~ 6000/cm
2, i.e. (3.75 ~ 4.5) × 10
5individual cells/T75, according to 4.5 × 10
5individual cells/T75 goes down to posterity.Culture vessel indicates the information such as cell algebraically and incubation time.Culture vessel is positioned over carbon dioxide constant temperature and humidity incubator to start to cultivate.Condition of culture: carbon dioxide constant temperature and humidity incubator.Condition: 37 ± 0.5 DEG C, carbon dioxide volume fraction is 5 ± 0.2%.Be cultured to cell fusion and reach 85% ~ 90%.
Cell separation, culture experiment result
Cell yield through said method is separated: 5 × 10
5~ 1 × 10
6cells/ml fat
Cultivate the 7th day, P1 can reach 1-2 doubly for the multiple of cell amplification;
Cultivate the 14th day, P2 can reach 4-6 doubly for the multiple of cell amplification;
Cultivate the 21st day, P3 can reach 10 times for the multiple of cell amplification.
The immunostained for analysis of embodiment 2 fat stem cell differentiation
2.1 adipogenic induction contrasts and oil red O stain experiment
By haMPCs with 1.5 × 10
5the density in cells/ hole is seeded in six orifice plates, and the sample cultivated with normal incubation medium is for becoming fat Analytical Chemical Experiment negative control group.Concrete grammar is: in basal medium (DMEM+10% hyclone), add the dexamethasone of 1 μm of ol/L, the insulin of 10 μm of ol/L, the indomethacin of 200 μm of ol/L and the isobutyl methylxanthine of 0.5mmol/L, be mixed with fat inducing culture, change weekly 2 not good liquors, observe until carry out into fat dyeing, above matched group all does parallel laboratory test (n=3).
With 0.5% oil red O, each group of sample after adipogenic induction is dyeed.Concrete operation method is: first rinsed fully by sample cell with D-hanks, then adds oil red dilution dyeing 10 ~ 15min.Carry out taking pictures observation with the adipogenic induction differentiation effect investigating co-culture method often to organize sample random selecting 5 ~ 10 visual field.As shown in Figure 1, the oil red O stain testing result of matched group (feminine gender) as shown in Figure 2 for the oil red O stain testing result of Adipocyte Differentiation.
Conclusion: this result shows that adipose-derived stem cells is under adipogenic induction agent effect, fat mesenchymal CFU-GM can generate lipid, have the ability being divided into adipose cell, the redness in Fig. 1 is that fat drips, and can see in the cell after fat differentiation and occur that intensive little fat together drips in a large number in figure.
2.2 osteoblast differentiation: the cell being cultured to the second filial generation, after trypsinization, with 1x10
5the inoculation of ml density is gone down to posterity, and changes inducing culture: DMEM/10%FBS, 0.1 μm of o/L dexamethasone, 50 μm of o/L vitamin Cs, 10mmol/ sodium β-glycerophosphate, 100U/ml penicillin, 100U/ml streptomycin after base culture base 1d; Every 3d replaced medium.During inducing culture 2 weeks, cell washs 2 times with PBS, fixes with 4% formaldehyde, 1% Alizarin red staining 10min, observed result under light microscopic.As shown in Figure 3, the cell dyeing testing result of matched group (feminine gender) as shown in Figure 4 for osteoblast differentiation Alizarin red staining testing result.
Conclusion: fat mesenchymal CFU-GM, after osteogenic induction cultivates 2 weeks, has Osteoblast Differentiation potential Alizarin red staining, has a large amount of red calcified matrix deposition in visible cell slurry.
The flow cytometer detection of embodiment 3 fat stem cell
By enzyme digestion by cell harvesting in centrifuge tube, cell suspension adjustment density be 1 × 10
5cells/mL, 1,800r/min (120g) centrifugal 5min, discards supernatant, rinses re-suspended cell with the cold D-Hanks of 4 DEG C, again by cell suspension with 800r/min, centrifugal 5min, afterwards supernatant discarded.Then with D-Hanks by resuspended for cell to 1mL, add antibody 5 ~ 10 μ L, lucifuge, places 30min on ice.Rinse with D-Hanks, centrifugal, abandon supernatant, repeat this flushing process 2 ~ 3 times, guarantee non-binding antibody Ex-all.Finally, the D-Hanks adding about 200 to 300 μ L makes suspension, uses flow cytomery.
The P3 that type i collagen enzymic digestion method is separated, cultivate for cell MSCs surface antigen streaming qualification result (flow cytometer detection test collection of illustrative plates) as shown in Figure 5.
Conclusion:
This result shows: this cell purity of analysis carrying out cell surface antigen markers expression to fat mesenchymal CFU-GM by flow cytometer is high, and major part is fat mesenchymal CFU-GM, and wherein CD34, CD45 are the negative marker of mesenchymal stem/progenitor cells.
Embodiment 4haMPC is to the therapeutic effect of hepatitis B
Method: the cell of results is injected 30ml normal saline, and be prepared into cell suspension, concentration is 2 × 10
5individual/ml, uses in order to feeding back.
After cell is successfully prepared, subcutaneous injection, injects weekly once, continuous surrounding.Before feeding back and after feeding back the 3rd, 6,12, within 24 months, carry out the curative effect doing clinical effectiveness scoring assessment fat mesenchymal CFU-GM treatment hepatitis B respectively.
Hepatitis B patient 2 example, respectively at cell feed back before, feeds back three months, after six months, blood drawing detection five indexes of hepatitis b, hepatitis B virus DNA and its result of ALT. as follows:
Patient 1, women, 48 years old age, and find hepatitis B and abnormal liver function in JIUYUE, 2009, in April, 2010 carries out haMPCs adoptive therapy.Particular exam index is as follows:
| Test item | Before feedback | Feed back latter 3 months | Feed back latter 6 months |
| Hepatitis B surface antigen | 6937 | 2634 | 1343 |
| Hepatitis B surface antibody | <2 | <2 | <2 |
| Hepatitis B virus e antigen | 0.493 | 0.363 | 0.173 |
| Hepatitis B e antibody | 0.003 | 0.003 | 0.003 |
| Hepatitis B core antibody | 0.005 | 0.005 | 0.005 |
| Hepatitis B virus DNA | 5.72*10^6 | 4.73*10^5 | 2.73*10^3 |
| ALT | 83 | 66 | 35 |
Patient 2, male, 42 years old age, in July, 2010 diagnosis of hepatitis b.Accept haMPCs adoptive therapy in November, 2010, treatment before and after look index is specific as follows:
| Test item | Before feedback | Feed back latter 3 months | Feed back latter 6 months |
| Hepatitis B surface antigen | 1805 | 1646 | 1255 |
| Hepatitis B surface antibody | <2.0 | <2.0 | <2.0 |
| Hepatitis B virus e antigen | 1284 | 1143 | 983 |
| Hepatitis B e antibody | 5.38 | 5.39 | 3.11 |
| Hepatitis B core antibody | 0.005 | 0.005 | 0.005 |
| Hepatitis B virus DNA | 4.73*10^4 | 3.73*10^4 | 6.27*10^3 |
| ALT | 63 | 54 | 28 |
Find out from above result, the cell mixture of haMPC has therapeutical effect for hepatitis B, and surface antigen can be made to decline, and viral DNA reduces, and lowers ALT, promotes the reparation of liver function.
The all documents mentioned in the present invention are quoted as a reference all in this application, are just quoted separately as a reference as each section of document.In addition should be understood that those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims limited range equally.
Claims (10)
1. a purposes for fat mesenchymal CFU-GM, is characterized in that, for the preparation of the pharmaceutical composition for the treatment of hepatitis B.
2. purposes as claimed in claim 1, it is characterized in that, described pharmaceutical composition comprises: fat mesenchymal CFU-GM, and pharmaceutically acceptable carrier.
3. purposes as claimed in claim 1, it is characterized in that, described treatment comprises the one or more target improvement being selected from lower group:
Hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B virus e antigen, hepatitis B e antibody, hepatitis B core antibody, hepatitis B virus DNA, and ALT.
4. purposes as claimed in claim 1, it is characterized in that, described fat mesenchymal CFU-GM has the arbitrary or various features being selected from lower group:
I the cell of () more than 80% has surface antigen CD29;
(ii) cell of more than 70% has surface antigen CD73;
(iii) cell of more than 60% has surface antigen CD105;
(iv) cell of more than 70% has surface antigen CD90.
5. purposes as claimed in claim 1 or 2, it is characterized in that, described fat mesenchymal CFU-GM has the arbitrary or various features being selected from lower group:
V (), in cell mass, the cell of less than 10% has surface antigen CD34;
(vi) in cell mass, the cell of less than 10% has surface antigen CD45.
6. for preventing or treat a pharmaceutical composition for hepatitis, it is characterized in that, described pharmaceutical composition comprises: the fat mesenchymal CFU-GM of effective dose, and pharmaceutically acceptable carrier.
7. pharmaceutical composition as claimed in claim 6, it is characterized in that, described pharmaceutical composition is intravenous injection reagent.
8. a method for prevention or treatment hepatitis, is characterized in that, comprise step: use fat mesenchymal CFU-GM or fat mesenchymal progenitor cell to the object of needs or contain the pharmaceutical composition of fat mesenchymal CFU-GM or fat mesenchymal progenitor cell.
9. method as claimed in claim 8, is characterized in that, described object is behaved or non-human mammal.
10. method as claimed in claim 8, it is characterized in that, described method of application is venous re-transfusion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310689278.XA CN104706673A (en) | 2013-12-16 | 2013-12-16 | Adipose-derived mesenchymal progenitor cells for treatment of hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310689278.XA CN104706673A (en) | 2013-12-16 | 2013-12-16 | Adipose-derived mesenchymal progenitor cells for treatment of hepatitis B |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104706673A true CN104706673A (en) | 2015-06-17 |
Family
ID=53406718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310689278.XA Pending CN104706673A (en) | 2013-12-16 | 2013-12-16 | Adipose-derived mesenchymal progenitor cells for treatment of hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104706673A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1673358A (en) * | 2005-03-17 | 2005-09-28 | 中国人民解放军军事医学科学院基础医学研究所 | Method for separating mesenchy mall stem/ancestral cells for bone parenchyma |
| WO2013017699A1 (en) * | 2011-08-04 | 2013-02-07 | Ethianum Betriebsgesellschaft Mbh & Co. Kg | Means and methods for liver regeneration |
-
2013
- 2013-12-16 CN CN201310689278.XA patent/CN104706673A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1673358A (en) * | 2005-03-17 | 2005-09-28 | 中国人民解放军军事医学科学院基础医学研究所 | Method for separating mesenchy mall stem/ancestral cells for bone parenchyma |
| WO2013017699A1 (en) * | 2011-08-04 | 2013-02-07 | Ethianum Betriebsgesellschaft Mbh & Co. Kg | Means and methods for liver regeneration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101914490B (en) | Human amnion mesenchymal stem cell serum-free culture medium and culture method thereof | |
| US9931445B2 (en) | System and methods for preparation of adipose-derived stem cells | |
| CN102485885A (en) | Separating method and application of fat stem cells | |
| CN101947318B (en) | Method for preparing porcine parvovirus inactivated vaccines | |
| CN108715830B (en) | Method for extracting exosome from urinary stem cell and application of exosome | |
| CN103849598A (en) | Method for preparing human adipose tissue-derived stromal cells | |
| CN105132369B (en) | A kind of derivant and inducing culture that mescenchymal stem cell is converted into testosterone secretion cell | |
| CN103301154B (en) | Application of umbilical cord mesenchymal stem cells in preparation of formulation for treating lupus erythematosus | |
| CN104651302A (en) | Method for extracting myelomonocyte and differentiating to osteoclast | |
| CN101831403B (en) | Method for amplifying mesenchymal stem cells of human umbilical cord and placenta in vitro | |
| CN116693666A (en) | Monoclonal antibody of anti-hepatitis B core antigen and application thereof | |
| CN105062970B (en) | A kind of derivant and induction differentiation complete medium that mescenchymal stem cell is induced to neuroblast | |
| CN103436555B (en) | Carry the adipose-derived mescenchymal stem cell of miR-122 in the application preparing treating liver fibrosis preparation | |
| CN103396985A (en) | Method for inducing differentiation of human umbilical cord mesenchymal stem cells into hepatocytes and applications | |
| WO2018161418A1 (en) | Humanized mouse model for hepatitis b constructed by using stem cells and application thereof | |
| CN102719397B (en) | Mesenchymal stem cell and application thereof in resisting HIV-1 (human immunodeficiency virus) | |
| CN105640993A (en) | Fat mesenchymal progenitor cell and platelet-rich blood plasma composition for treatment of hepatitis B | |
| CN105886462A (en) | Composition ADSCs for ADSCs culture and ADSCs culture method | |
| CN105663163A (en) | Human adipose derived mesenchymal progenitor cells for treating hepatitis B | |
| CN104706673A (en) | Adipose-derived mesenchymal progenitor cells for treatment of hepatitis B | |
| CN104706670A (en) | Fat mesenchymal progenitor cell and platelet-rich blood plasma composition for hepatitis B treatment | |
| CN101412987A (en) | Method for amplifying in vitro mesenchymal stem cells | |
| CN111419848A (en) | Pharmaceutical composition for inducing stem cell chondrogenic differentiation and application thereof | |
| CN104706674A (en) | Fat mesenchymal progenitor cell and fat matrix vascular component composition for hepatitis B treatment | |
| CN105112367B (en) | A kind of mescenchymal stem cell epidermal differentiation derivant and its application process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150617 |
|
| WD01 | Invention patent application deemed withdrawn after publication |